A Phase 1 interventional study of Oral Lenacapavir and Subcutaneous Lenacapavir in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 23 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-01-27.
Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate the safety and tolerability of a combination of the broadly neutralizing antibodies (bNAbs) teropavimab (formerly GS-5423) and zinlirvimab (formerly GS-2872) in combination with the HIV capsid inhibitor lenacapavir (LEN).
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Proviral phenotypic sensitivity to both teropavimab and zinlirvimab at screening by the PhenoSense mAb Assay (Monogram Biosciences) for inclusion in the Primary Cohort; sensitivity at screening by the PhenoSense mAb Assay (Monogram Biosciences) to 1 mAb, either teropavimab or zinlirvimab, within 18 months prior to enrollment for inclusion in the optional Pilot Cohort
-- In both cohorts, teropavimab sensitivity is defined as 90% inhibitory concentration (IC90) ≤ 2 μg/mL; zinlirvimab sensitivity is defined as IC90 ≤ 2 μg/mL;
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a loading dose of 600 milligrams (mg) LEN orally on Day 1 and Day 2, along with 927 mg LEN as subcutaneous (SC) injection on Day 1. Thereafter, participants will receive 30 mg/kg teropavimab and then 10 mg/kg zinlirvimab as an intravenous (IV) infusion on Day 1.
Drug: Oral Lenacapavir · Drug: Subcutaneous Lenacapavir · Drug: Teropavimab · Drug: Zinlirvimab
Participants will receive a loading dose of 600 mg LEN orally on Day 1 and Day 2, along with 927 mg LEN as SC injection on Day 1. Thereafter, participants will receive 30 mg/kg teropavimab and then 30 mg/kg zinlirvimab as an IV infusion on Day 1.
Drug: Oral Lenacapavir · Drug: Subcutaneous Lenacapavir · Drug: Teropavimab · Drug: Zinlirvimab
Participants will receive a loading dose of 600 mg LEN orally on Day 1 and Day 2, along with 927 mg LEN as SC injection on Day 1. Thereafter, participants will receive 30 mg/kg teropavimab and then 10 mg/kg zinlirvimab as an IV infusion on Day 1.
Drug: Oral Lenacapavir · Drug: Subcutaneous Lenacapavir · Drug: Teropavimab · Drug: Zinlirvimab
Participants will receive a loading dose of 600 mg LEN orally on Day 1 and Day 2, along with 927 mg LEN as SC injection on Day 1. Thereafter, participants will receive 30 mg/kg teropavimab and then 30 mg/kg zinlirvimab as an IV infusion on Day 1.
Drug: Oral Lenacapavir · Drug: Subcutaneous Lenacapavir · Drug: Teropavimab · Drug: Zinlirvimab
Tablets administered without regard to food
Also known as: GS-6207
Administered in the abdomen via subcutaneous injections
Also known as: GS-6207
Administered intravenously
Also known as: 3BNC117-LS, GS-5423
Administered intravenously
Also known as: 10-1074-LS, GS-2872
Primary Cohort: Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs)
A treatment emergent SAE was defined as an event that, at any dose, resulted in the following: death; life-threatening situation; in-patient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; a congenital anomaly/birth defect; a medically important event or reaction: such events may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent one of the other outcomes constituting SAEs. These events had an onset date on or after the study drug start date and prior to the last exposure date of long-acting (LA) regimen period for the LA regimen period analysis. The long acting regimen period included participants who were randomized and received at least one dose of the complete LA study drug regimen (ie, SC LEN + Teropavimab + Zinlirvimab).
Time frame: Day 1 up to Week 26
Primary Cohort: Percentage of Participants With Human Immunodeficiency Virus- 1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 26 as Determined by the US Food and Drug Administration (FDA)-Defined Snapshot Algorithm
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 26 was analyzed using the snapshot algorithm, which defined a participant's virologic outcome and included participants who had the last available on-treatment HIV-1 RNA \< 50 copies/mL in the Week 26 analysis window. Week 26 window was between Days 176 and 224 (inclusive).
Time frame: Week 26
Primary Cohort: Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 26 as Determined by the US FDA-defined Snapshot Algorithm
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 26 was analyzed using the snapshot algorithm, which defined a participant's virologic outcome and included participants a) who had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 26 analysis window; b) who did not have on-treatment HIV-1 RNA data in the Week 26 analysis window and i) discontinued study drug prior to or in the Week 26 analysis window due to lack of efficacy, or ii) discontinued study drug prior to or in the Week 26 analysis window due to AE or death and had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL, or iii) discontinued study drug prior to or in the Week 26 analysis window due to reasons other than AE, death, or lack of efficacy and had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL. Week 26 window was between Days 176 and 224 (inclusive).
Time frame: Week 26
Primary Cohort: Percentage of Participants With Positive Anti-Teropavimab Antibodies
Anti-teropavimab antibodies positive participants are participants with positive treatment-emergent anti-drug antibody.
Time frame: Week 26
Primary Cohort: Percentage of Participants With Positive Anti-zinlirvimab Antibodies
Anti-zinlirvimab antibodies positive participants are participants with positive treatment-emergent anti-drug antibody.
Time frame: Week 26
Primary Cohort: Change From Baseline in Cluster Determinant 4+ (CD4+) Cell Count at Week 26
Time frame: Baseline; Week 26
Primary Cohort: Number of Participants Who Develop Treatment-Emergent Resistance to LEN, Teropavimab, and Zinlirvimab
Participants in the Resistance Analysis Population analyzed for this outcome included any participant who had received 1 dose of study drug, maintained their study drug regimen, and met one of the following virologic failure criteria: * Participants with HIV-1 RNA \>/= 200 copies/mL on 2 consecutive visits * Participants with HIV-1 RNA \>/= 200 copies/mL at study discontinuation or Week 26.
Time frame: Day 1 up to Week 26
Primary Cohort: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
TEAEs were those adverse events that began on or after the first dose date of study drug and prior to last exposure date of LA regimen from participants who prematurely discontinued study or completed study, or any adverse events led to premature study drug discontinuation.
Time frame: Day 1 up to Week 26
Primary Cohort: Pharmacokinetic (PK) Parameter: AUC0-26 of Teropavimab
AUC0-26 is defined as the concentration of drug over time from Week zero to Week 26.
Time frame: Predose and at End of Infusion (EOI) of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26
Primary Cohort: PK Parameter: AUC0-26 of Zinlirvimab
AUC0-26 is defined as the concentration of drug over time from Week zero to Week 26.
Time frame: Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26
Primary Cohort: PK Parameter: AUClast of Teropavimab
AUClast is defined as the concentration of drug from time zero to the last observable concentration.
Time frame: Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)
Primary Cohort: PK Parameter: AUClast of Zinlirvimab
AUClast is defined as the concentration of drug from time zero to the last observable concentration.
Time frame: Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)
Primary Cohort: PK Parameter: T1/2 of LEN
T1/2 is defined as the estimate of the terminal elimination half-life of the drug.
Time frame: Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)
Primary Cohort: PK Parameter: T1/2 of Teropavimab
T1/2 is defined as the estimate of the terminal elimination half-life of the drug.
Time frame: Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)
Primary Cohort: PK Parameter: T1/2 of Zinlirvimab
T1/2 is defined as the estimate of the terminal elimination half-life of the drug.
Time frame: Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)
Primary Cohort: PK Parameter: Cmax of Teropavimab
Cmax is defined as the maximum observed concentration of drug.
Time frame: Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)
Primary Cohort: PK Parameter: Cmax of Zinlirvimab
Cmax is defined as the maximum observed concentration of drug.
Time frame: Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)
Primary Cohort: PK Parameter: Tmax of Teropavimab
Tmax is defined as the time (observed time point) of Cmax.
Time frame: Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)
Primary Cohort: PK Parameter: Tmax of Zinlirvimab
Tmax is defined as the time (observed time point) of Cmax.
Time frame: Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)
Primary Cohort: PK Parameter: Tlast of LEN
Tlast is defined as the time (observed time point) of Clast (the last observable concentration of drug).
Time frame: Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)
Primary Cohort: PK Parameter: Tlast of Teropavimab
Tlast is defined as the time (observed time point) of Clast (the last observable concentration of drug).
Time frame: Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)
Primary Cohort: PK Parameter: Tlast of Zinlirvimab
Tlast is defined as the time (observed time point) of Clast (the last observable concentration of drug).
Time frame: Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)
Primary Cohort: PK Parameter: C26week of LEN
C26week is the concentration at week 26.
Time frame: Week 26
Primary Cohort: PK Parameter: C26week of Teropavimab
C26week is the concentration at week 26.
Time frame: Week 26
Primary Cohort: PK Parameter: C26week of Zinlirvimab
C26week is the concentration at week 26.
Time frame: Week 26
Participants were enrolled at study sites in the United States.
| Milestone | Primary Cohort: Lenacapavir (LEN)+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg | Pilot Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Pilot Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|---|---|
| Started | 11 | 10 | 5 | 6 |
| Completed | 8 | 9 | 5 | 6 |
| Not completed | 3 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 1 | 1 | 0 | 0 |
A treatment emergent SAE was defined as an event that, at any dose, resulted in the following: death; life-threatening situation; in-patient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; a congenital anomaly/birth defect; a medically important event or reaction: such events may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent one of the other outcomes constituting SAEs. These events had an onset date on or after the study drug start date and prior to the last exposure date of long-acting (LA) regimen period for the LA regimen period analysis. The long acting regimen period included participants who were randomized and received at least one dose of the complete LA study drug regimen (ie, SC LEN + Teropavimab + Zinlirvimab).
| percentage of participants | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|
| Primary Cohort: Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs) | 0 | 0 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 26 was analyzed using the snapshot algorithm, which defined a participant's virologic outcome and included participants who had the last available on-treatment HIV-1 RNA \< 50 copies/mL in the Week 26 analysis window. Week 26 window was between Days 176 and 224 (inclusive).
| percentage of participants | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|
| Primary Cohort: Percentage of Participants With Human Immunodeficiency Virus- 1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 26 as Determined by the US Food and Drug Administration (FDA)-Defined Snapshot Algorithm | 90.0 (55.5 to 99.7) | 90.0 (55.5 to 99.7) |
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 26 was analyzed using the snapshot algorithm, which defined a participant's virologic outcome and included participants a) who had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 26 analysis window; b) who did not have on-treatment HIV-1 RNA data in the Week 26 analysis window and i) discontinued study drug prior to or in the Week 26 analysis window due to lack of efficacy, or ii) discontinued study drug prior to or in the Week 26 analysis window due to AE or death and had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL, or iii) discontinued study drug prior to or in the Week 26 analysis window due to reasons other than AE, death, or lack of efficacy and had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL. Week 26 window was between Days 176 and 224 (inclusive).
| percentage of participants | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|
| Primary Cohort: Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 26 as Determined by the US FDA-defined Snapshot Algorithm | 10.0 (0.3 to 44.5) | 0 (0.0 to 30.8) |
Anti-teropavimab antibodies positive participants are participants with positive treatment-emergent anti-drug antibody.
| percentage of participants | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|
| Primary Cohort: Percentage of Participants With Positive Anti-Teropavimab Antibodies | 50.0 | 10.0 |
Anti-zinlirvimab antibodies positive participants are participants with positive treatment-emergent anti-drug antibody.
| percentage of participants | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|
| Primary Cohort: Percentage of Participants With Positive Anti-zinlirvimab Antibodies | 40.0 | 20.0 |
| cells per microliter (cells/µL) | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|
| Baseline | 903 ± 303.7 | 1086 ± 333.6 |
| Week 26 | -25 ± 241.6 | -5 ± 162.2 |
Participants in the Resistance Analysis Population analyzed for this outcome included any participant who had received 1 dose of study drug, maintained their study drug regimen, and met one of the following virologic failure criteria: * Participants with HIV-1 RNA \>/= 200 copies/mL on 2 consecutive visits * Participants with HIV-1 RNA \>/= 200 copies/mL at study discontinuation or Week 26.
| Participants | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|
| Participants who developed resistance to LEN | 1 | — |
| Participants who developed resistance to Teropavimab | 0 | — |
| Participants who developed resistance to Zinlirvimab | 0 | — |
TEAEs were those adverse events that began on or after the first dose date of study drug and prior to last exposure date of LA regimen from participants who prematurely discontinued study or completed study, or any adverse events led to premature study drug discontinuation.
| percentage of participants | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|
| Primary Cohort: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) | 90 | 100 |
AUC0-26 is defined as the concentration of drug over time from Week zero to Week 26.
| day* μg/mL | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|
| Primary Cohort: Pharmacokinetic (PK) Parameter: AUC0-26 of Teropavimab | 30500 ± 2270 | 31600 ± 3750 |
AUC0-26 is defined as the concentration of drug over time from Week zero to Week 26.
| day* μg/mL | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|
| Primary Cohort: PK Parameter: AUC0-26 of Zinlirvimab | 14800 ± 2090 | 46100 ± 4180 |
AUClast is defined as the concentration of drug from time zero to the last observable concentration.
| day* μg/mL | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|
| Primary Cohort: PK Parameter: AUClast of Teropavimab | 32900 ± 3140 | 34400 ± 5500 |
AUClast is defined as the concentration of drug from time zero to the last observable concentration.
| day* μg/mL | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|
| Primary Cohort: PK Parameter: AUClast of Zinlirvimab | 17100 ± 2640 | 54700 ± 5290 |
T1/2 is defined as the estimate of the terminal elimination half-life of the drug.
| day | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|
| Primary Cohort: PK Parameter: T1/2 of LEN | 65.8 (33.9 to 99.3) | 69.8 (55.1 to 140) |
T1/2 is defined as the estimate of the terminal elimination half-life of the drug.
| day | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|
| Primary Cohort: PK Parameter: T1/2 of Teropavimab | 65.2 (54.3 to 78.3) | 70.5 (57.5 to 89.6) |
T1/2 is defined as the estimate of the terminal elimination half-life of the drug.
| day | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|
| Primary Cohort: PK Parameter: T1/2 of Zinlirvimab | 76.7 (43.4 to 113) | 84.5 (71.6 to 149) |
Cmax is defined as the maximum observed concentration of drug.
| μg/mL | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|
| Primary Cohort: PK Parameter: Cmax of Teropavimab | 1090 ± 160 | 1090 ± 222 |
Cmax is defined as the maximum observed concentration of drug.
| μg/mL | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|
| Primary Cohort: PK Parameter: Cmax of Zinlirvimab | 378 ± 57.5 | 1110 ± 187 |
Tmax is defined as the time (observed time point) of Cmax.
| hours | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|
| Primary Cohort: PK Parameter: Tmax of Teropavimab | 1.16 (1.02 to 2.75) | 2.24 (0.983 to 2.83) |
Tmax is defined as the time (observed time point) of Cmax.
| hours | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|
| Primary Cohort: PK Parameter: Tmax of Zinlirvimab | 1.10 (0.983 to 1.37) | 1.00 (0.850 to 1.23) |
Tlast is defined as the time (observed time point) of Clast (the last observable concentration of drug).
| day | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|
| Primary Cohort: PK Parameter: Tlast of LEN | 364 (168 to 366) | 364 (84.0 to 373) |
Tlast is defined as the time (observed time point) of Clast (the last observable concentration of drug).
| day | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|
| Primary Cohort: PK Parameter: Tlast of Teropavimab | 364 (168 to 366) | 364 (83.9 to 373) |
Tlast is defined as the time (observed time point) of Clast (the last observable concentration of drug).
| day | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|
| Primary Cohort: PK Parameter: Tlast of Zinlirvimab | 364 (168 to 366) | 364 (83.9 to 373) |
C26week is the concentration at week 26.
| ng/mL | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|
| Primary Cohort: PK Parameter: C26week of LEN | 27.2 ± 17.4 | 22.5 ± 17.0 |
C26week is the concentration at week 26.
| μg/mL | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|
| Primary Cohort: PK Parameter: C26week of Teropavimab | 38.4 ± 5.89 | 42.7 ± 6.49 |
C26week is the concentration at week 26.
| μg/mL | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|
| Primary Cohort: PK Parameter: C26week of Zinlirvimab | 27.2 ± 6.44 | 84.6 ± 27.1 |
Collected over All-Cause Mortality: Up to 55.9 weeks; Adverse Events: Up to 51.1 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | 0/11 (0%) | 2/11 (18.2%) | 9/11 (81.8%) |
| Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Pilot Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | 0/5 (0%) | 1/5 (20%) | 4/5 (80%) |
| Pilot Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Event | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg | Pilot Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Pilot Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|---|---|
| Soft tissue infectionInfections and infestations | 0/11 | 0/10 | 1/5 | 0/6 |
| Myocardial infarctionCardiac disorders | 1/11 | 0/10 | 0/5 | 0/6 |
| PneumoniaInfections and infestations | 1/11 | 0/10 | 0/5 | 0/6 |
| Event | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg | Pilot Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Pilot Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg |
|---|---|---|---|---|
| Injection site indurationGeneral disorders | 2/11 | 4/10 | 0/5 | 3/6 |
| Injection site painGeneral disorders | 5/11 | 5/10 | 0/5 | 2/6 |
| Injection site erythemaGeneral disorders | 4/11 | 3/10 | 0/5 | 2/6 |
| Injection site noduleGeneral disorders | 4/11 | 2/10 | 1/5 | 1/6 |
| Covid-19Infections and infestations | 4/11 | 1/10 | 1/5 | 1/6 |
| Injection site pruritusGeneral disorders | 1/11 | 0/10 | 0/5 | 2/6 |
| Injection site massGeneral disorders | 3/11 | 1/10 | 0/5 | 0/6 |
| Upper respiratory tract infectionInfections and infestations | 3/11 | 0/10 | 0/5 | 1/6 |
| LymphadenopathyBlood and lymphatic system disorders | 0/11 | 2/10 | 0/5 | 0/6 |
| Conjunctival haemorrhageEye disorders | 0/11 | 0/10 | 1/5 | 0/6 |
The Safety Analysis Set included all randomized participants who have received at least one dose of study drug.
| Age, Categorical(Participants) | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg | Pilot Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Pilot Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 11 | 10 | 5 | 6 | 32 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg | Pilot Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Pilot Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg | Total |
|---|---|---|---|---|---|
| Mean | 45 ± 9.8 | 41 ± 11.1 | 47 ± 15.1 | 46 ± 11.4 | 44 ± 11.1 |
| Sex: Female, Male(Participants) | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg | Pilot Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Pilot Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg | Total |
|---|---|---|---|---|---|
| Female | 0 | 3 | 2 | 1 | 6 |
| Male | 11 | 7 | 3 | 5 | 26 |
| Ethnicity (NIH/OMB)(Participants) | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg | Pilot Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Pilot Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 3 | 2 | 1 | 10 |
| Not Hispanic or Latino | 7 | 7 | 3 | 5 | 22 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg | Pilot Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Pilot Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg | Total |
|---|---|---|---|---|---|
| Race — White | 7 | 5 | 3 | 3 | 18 |
| Race — Black or African American | 1 | 2 | 2 | 2 | 7 |
| Race — Other or More Than One Race | 1 | 2 | 0 | 1 | 4 |
| Race — Asian | 2 | 1 | 0 | 0 | 3 |
| Region of Enrollment(Participants) | Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg | Pilot Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg | Pilot Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg | Total |
|---|---|---|---|---|---|
| United States | 11 | 10 | 5 | 6 | 32 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2021 to primary completion in Jun 2022, 14 months.
Results were first posted in Jan 2025, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lenacapavir · Teropavimab · Zinlirvimab